This review included studies reporting MRSA prevalence between 2000 and 2016. Studies were excluded if they did not contain complete information on antimicrobial susceptibility testing (AST) methods. Primary outcomes were the proportion of MRSA among S. aureus isolates (resistance proportion) or among individual samples (prevalence).
A total of 229 studies in 19 countries/territories were included in the study. There was substantial heterogeneity in both outcomes (resistance proportion, I2=99.59%; prevalence, I2=99.83%), precluding pooled averages, and meta-regression analyses revealed that these variations were explained by country income status and participant characteristics but not by methodological differences in AST. Also, no significant secular changes in MRSA prevalence or resistance proportions in Asia-Pacific were found.
The resistance proportions and prevalence of MRSA infections in Asia-Pacific are comparable with those reported in other regions with no significant secular changes in the past decade. Country income status and characteristics of the sample population explained more variation in the reported resistance proportions and prevalence of MRSA than methodological differences in AST across locations in the region.
本综述包括报告2000年至2016年间MRSA患病率的研究。如果研究不包含有关抗菌药物敏感性测试(AST)方法的完整信息,则将其排除在外。主要结果是金黄色葡萄球菌分离株中MRSA的比例(耐药比例)或个体样本中MRSA的比例(患病率)。
在19个国家/地区共纳入229项研究。两种结果均存在实质性异质性(抗性比例,I2=99.59%;患病率,I2=99.83%),排除汇总平均值,和荟萃回归分析显示,这些差异是由国家收入状况和参与者特征解释的,而不是由AST的方法差异解释的。此外,在亚太地区没有发现MRSA患病率或耐药比例的显著长期变化.
亚太地区MRSA感染的耐药比例和流行率与其他地区的报告相当,在过去十年中没有显著的长期变化。国家收入状况和样本人群的特征解释了报告的MRSA耐药比例和患病率的差异,而不是该地区各个地区AST的方法学差异。